- Investing Ideas
- U.S. Pharmaceuticals & Biotech Healthy potentially undervalued
U.S. Pharmaceuticals & Biotech Healthy potentially undervalued
Results
77
Companies which are potentially undervalued and in an acceptable financial position.
77 companies
Trulieve Cannabis
Market Cap: US$2.1b
Operates as a cannabis retailer in the United States.
TRLV
US$11.32
7D
16.8%
1Y
27.2%
United Therapeutics
Market Cap: US$22.0b
Engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
UTHR
US$518.53
7D
0.05%
1Y
67.7%
CorMedix
Market Cap: US$645.4m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$8.56
7D
4.8%
1Y
-38.8%
Supernus Pharmaceuticals
Market Cap: US$2.6b
A biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.
SUPN
US$45.36
7D
-7.5%
1Y
2.3%
Elanco Animal Health
Market Cap: US$12.2b
An animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.
ELAN
US$25.09
7D
6.1%
1Y
40.2%
Prestige Consumer Healthcare
Market Cap: US$2.5b
Develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally.
PBH
US$51.45
7D
1.7%
1Y
-22.5%
ANI Pharmaceuticals
Market Cap: US$1.6b
A biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally.
ANIP
US$75.65
7D
-1.6%
1Y
-17.7%
Tarsus Pharmaceuticals
Market Cap: US$3.2b
A commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.
TARS
US$71.45
7D
0.6%
1Y
21.4%
Journey Medical
Market Cap: US$223.3m
A commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
DERM
US$7.53
7D
13.1%
1Y
1.5%
Fennec Pharmaceuticals
Market Cap: US$399.8m
Operates as a commercial stage biopharmaceutical company in the United States.
FENC
US$11.71
7D
-1.3%
1Y
34.9%
Viatris
Market Cap: US$19.0b
Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.
VTRS
US$16.72
7D
3.4%
1Y
60.6%
Verastem
Market Cap: US$621.3m
A development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.
VSTM
US$7.08
7D
-4.7%
1Y
-20.4%
Protara Therapeutics
Market Cap: US$228.7m
A clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases.
TARA
US$3.97
7D
-0.3%
1Y
26.8%
ACADIA Pharmaceuticals
Market Cap: US$5.1b
A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACAD
US$30.57
7D
1.3%
1Y
18.9%
Amphastar Pharmaceuticals
Market Cap: US$915.4m
A bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.
AMPH
US$21.98
7D
3.0%
1Y
-27.6%
Madrigal Pharmaceuticals
Market Cap: US$11.8b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$512.16
7D
-2.3%
1Y
20.5%
Vanda Pharmaceuticals
Market Cap: US$322.3m
A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
VNDA
US$5.44
7D
0%
1Y
16.5%
Zevra Therapeutics
Market Cap: US$691.8m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$12.04
7D
4.1%
1Y
27.9%
TG Therapeutics
Market Cap: US$7.9b
A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
TGTX
US$55.42
7D
10.3%
1Y
96.0%
Exelixis
Market Cap: US$13.5b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$56.72
7D
6.8%
1Y
47.9%
ADMA Biologics
Market Cap: US$2.1b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$9.72
7D
1.9%
1Y
-43.2%
Innoviva
Market Cap: US$1.5b
Operates as a biopharmaceutical company in the United States and internationally.
INVA
US$21.17
7D
-0.4%
1Y
6.2%
Phibro Animal Health
Market Cap: US$1.4b
Operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific.
PAHC
US$35.93
7D
3.7%
1Y
10.1%
Verrica Pharmaceuticals
Market Cap: US$83.7m
A dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States.
VRCA
US$4.94
7D
5.6%
1Y
-17.3%
Assembly Biosciences
Market Cap: US$719.3m
A biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide.
ASMB
US$35.33
7D
10.0%
1Y
37.9%
Bruker
Market Cap: US$8.7b
Develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions.
BRKR
US$56.85
7D
-0.02%
1Y
66.9%
Bristol-Myers Squibb
Market Cap: US$137.4b
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
BMY
US$67.92
7D
2.8%
1Y
43.9%
Neurocrine Biosciences
Market Cap: US$15.6b
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
NBIX
US$153.37
7D
-0.6%
1Y
12.1%
TriSalus Life Sciences
Market Cap: US$314.6m
Engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.
TLSI
US$5.03
7D
-6.9%
1Y
-1.4%
TScan Therapeutics
Market Cap: US$54.2m
A clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States.
TCRX
US$0.79
7D
-3.8%
1Y
-58.0%
Zoetis
Market Cap: US$31.9b
Engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
ZTS
US$77.29
7D
4.5%
1Y
-50.1%
Ardelyx
Market Cap: US$932.0m
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$3.78
7D
-3.6%
1Y
-39.0%
ICON
Market Cap: US$13.4b
A clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally.
ICLR
US$168.91
7D
1.1%
1Y
-1.7%
Precision BioSciences
Market Cap: US$233.2m
A clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States.
DTIL
US$8.55
7D
3.9%
1Y
69.6%
BioMarin Pharmaceutical
Market Cap: US$12.6b
A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
BMRN
US$66.12
7D
-1.3%
1Y
15.1%
Gilead Sciences
Market Cap: US$182.0b
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
GILD
US$148.77
7D
3.7%
1Y
29.6%